|Dr. Franz-Werner Haas L.L.M., LLD, Ph.D., LL.M.||CEO, COO & Member of Management Board||N/A||N/A||1970|
|Dr. Florian von der Mulbe M.B.A., Ph.D., MBA||Co-Founder, Member of Management Board & Chief Production Officer||N/A||N/A||1973|
|Mr. Pierre Kemula B.Sc.||CFO & Member of Management Board||N/A||N/A||1974|
|Ms. Mariola Fotin-Mleczek||CTO & Member of Management Board||N/A||N/A||1968|
|Dr. Igor Splawski M.Sc., Ph.D.||Chief Scientific Officer & Member of Management Board||N/A||N/A||1969|
|Dr. Ingmar Hoerr||Co-Founder, CEO & Supervisory Board Chairman (Leave of Absence)||N/A||N/A||N/A|
|Dr. Bernd Winterhalter M.D., Ph.D.||Interim Chief Devel. Officer||N/A||N/A||1959|
|Dr. Sarah Fakih||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Thorsten SchÃ¼ller||Head of Corp. Communications||N/A||N/A||N/A|
|Slavica Stevanovic-Heck||Head of HR||N/A||N/A||N/A|
CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy and in combination with anti-PD-1; and CV7202, which is in a Phase 1 clinical trials as a vaccine candidate against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase 1 clinical trial. The company's partnered programs comprise BI1361849, a therapeutic vaccine candidate that is in a Phase 1/2 clinical trials to elicit antigen-specific immune responses against tumor-associated antigens frequently overexpressed in patients with non-small cell lung cancer; Cas9 mRNA constructs for use in gene editing therapeutics; mRNA based novel therapeutic antibodies; prophylactic vaccines to prevent picornaviruses, influenza, malaria, and rotavirus; and programs against SARS-CoV-2, Lassa virus, and yellow fever. It has strategic partnerships with Genmab, Arcturus, Acuitas, CRISPR Therapeutics, Boehringer Ingelheim, GlaxoSmithKline, the Bill & Melinda Gates Foundation, CEPI, Tesla Grohmann, and others, as well as a collaboration with the U.K. Government to develop and manufacture potential vaccine candidates against SARS-CoV-2 variants. The company was founded in 2000 and is headquartered in TÃ¼bingen, Germany.
CureVac N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.